Effects of the β2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravis

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Ghazanfari, Nazanin ^a   Morsch, Marco ^a   Tse, Nigel ^a   Reddel, Stephen W ^b   Phillips, William D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; SALBUTAMOL; SYNAPTOPHYSIN; AUTOANTIBODY; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; MUSK PROTEIN, MOUSE; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAPHRAGM MUSCLE; DRUG MECHANISM; ENDPLATE POTENTIAL; FEMALE; GASTROCNEMIUS MUSCLE; MOUSE; MUSCLE CELL; MYASTHENIA GRAVIS; NERVE ENDING; NEUROMUSCULAR SYNAPSE; NONHUMAN; PROTEIN LOCALIZATION; WEAKNESS; WEIGHT REDUCTION; ANIMAL; CHEMICALLY INDUCED DISORDER; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; HUMAN; IMMUNOLOGY; PATHOLOGY; SKELETAL MUSCLE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ANIMALS; AUTOANTIBODIES; FEMALE; HUMANS; MICE; MUSCLE, SKELETAL; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; NEUROMUSCULAR JUNCTION; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84895558244     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087840     Document Type: Article

References (64)

1. Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, and future. J Clin Invest. 116: 2843-2854. (Pubitemid 44684466)
2. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, et al. (2001) Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7: 365-368. (Pubitemid 32224355)
3. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalf R, et al. (2004) Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 55: 580-584. (Pubitemid 38391977)
4. Pevzner A, Schoser B, Peters K, Cosma NC, Karakatsani A, et al. (2011) Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 259: 427-435.
5. Higuchi O, Hamuro J, Motomura M, Yamanashi Y (2011) Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69: 418-422.
6. Glass DJ, Bowen DC, Stitt TN, Radiejewski C, Brunno J, et al. (1996) Agrin acts via a MuSK receptor complex. Cell 85: 513-523. (Pubitemid 26157190)
7. Kim N, Burden SJ (2008) MuSK controls where motor axons grow and form synapses. Nat Neurosci 11: 19-27.
8. Zhang B, Luo S, Wang Q, Suzuki T, Xiong WC, et al. (2008) LRP4 Serves as a Coreceptor of Agrin. Neuron 60: 285-297.
9. Inoue A, Setoguchi K, Matsubara Y, Okada K, Sato N, et al. (2009) Dok-7 activates the muscle receptor kinase MuSK and shapes synapse formation. Science Signaling 2: ra7.
10. Bergamin E, Hallock PT, Burden SJ, Hubbard SR (2010) The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization. Molecular Cell 39: 100-109.
11. Wu H, Xiong WC, Mei L (2010) To build a synapse: signaling pathways in neuromuscular junction assembly. Development 137: 1017-1033.
12. Ghazanfari N, Fernandez KJ, Murata Y, Morsch M, Ngo ST, et al. (2011) Muscle Specific Kinase: Organiser of synaptic membrane domains. Int J Biochem Cell Biol 43: 295-298.
13. Walker MB (1973) Some discoveries on myasthenia gravis: the background. Br Med J 2: 42-43.
14. Bestue-Cardiel M, Sáenz de Cabezón-Alvarez A, Capablo-Liesa JL, López-Pisón J, Peña-Segura JL, et al. (2005) Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology 65: 144-146. (Pubitemid 40967793)
15. Mihaylova V, Müller JS, Vilchez JJ, Salih MA, Kabiraj MM, et al. (2008) Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain 131: 747-759. (Pubitemid 351294715)
16. Schara U, Barisic N, Deschauer M, Lindberg C, Straub V, et al. (2009) Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul Disord 19 828-832.
17. Lashley D, Palace J, Jayawant S, Robb S, Beeson D (2010) Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology 74: 1517-1523.
18. Liewluck T, Selcen D, Engel AG (2011) Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle Nerve 44: 789-794.
19. Sadeh M, Shen XM, Engel AG (2011) Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon-subunit mutations. Muscle Nerve 44: 289-291.
20. Chan SH, Wong VC, Engel AG (2012) Neuromuscular junction acetylcholin-esterase deficiency responsive to albuterol. Pediatr Neurol 47: 137-140.
21. Webster RG, Cossins J, Lashley D, Maxwell S, Liu WW, et al. (2013) A mouse model of the slow channel myasthenic syndrome: Neuromuscular physiology and effects of ephedrine treatment. Exp Neurol 248: 286-298.
22. Guptill JT, Sanders DB, Evoli A (2011) Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 44: 36-40.
23. Riminton DS, Hartung HP, Reddel SW (2011) Managing the risks of immunosuppression. Curr Opin Neurol 24: 217-223.
24. Díaz-Manera J, Martínez-Hernández E, Querol L, Klooster R, Rojas-García R, et al. (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78: 189-193.
25. Drachman DB (1994) Myasthenia gravis. N Engl J Med 330: 1797-1810.
26. Richman DP, Agius MA (2003) Treatment of autoimmune myasthenia gravis. Neurology 61: 1652-1661. (Pubitemid 38020807)
27. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, et al. (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17: 893-902.
28. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, et al. (2003) Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126: 2304-2311. (Pubitemid 37432373)
29. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A (2003) Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60: 1978-1980. (Pubitemid 36736017)
30. Hatanaka Y, Hemmi S, Morgan MB, Scheufele ML, Claussen GC, et al. (2005) Nonresponsiveness to acetylcholinesterase agents in patients with MuSK-antibody-positive MG. Neurology 65: 1508-1509. (Pubitemid 41552801)
31. Morsch M, Reddel SW, Ghazanfari N, Toyka KV, Phillips WD (2013) Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by Muscle Specific Kinase autoantibody. J Physiol 591: 2747-2762.
32. Shigemoto K, Kubo S, Maruyama N, Hato N, Yamada H, et al. (2006) Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 116: 1016-1024.
33. Cole RN, Reddel SW, Gervásio OL, Phillips WD (2008) Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 63: 782-789. (Pubitemid 351945537)
34. Punga AR, Lin S, Oliveri F, Meinen S, Ruegg MA (2011) Muscle-selective synaptic disassembly and reorganization in MuSK antibody-positive MG mice. Exp Neurol 230: 207-217.
35. Richman DP, Nishi K, Morell SW, Chang JM, Ferns MJ, et al. (2011) Acute severe animal modelof anti-Muscle-specific kinase myasthenia. Arch Neurol. 69: 453-460.
36. Klooster R, Plomp JJ, Huijbers MG, Niks EH, Straasheijm KR, et al. (2012) Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 135: 1081-1101.
37. Viegas S, Jacobson L, Waters P, Cossins J, Jacob S, et al. (2012) Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects. Exp Neurol 234: 506-512.
38. Morsch M, Reddel SW, Ghazanfari N, Toyka KV, Phillips WD (2012) Muscle Specific Kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors. Exp Neurol 237: 286-295.
39. Ohta K, Shigemoto K, Fujinami A, Maruyama N, Konishi T, et al. (2007) Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol 14: 1029-1034. (Pubitemid 47300778)
40. Mori S, Kubo S, Akiyoshi T, Yamada S, Miyazaki T, et al. (2012) Antibodies against Muscle-Specific Kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Path 180: 798-810.
41. Cole RN, Ghazanfari N, Ngo ST, Gervasio OL, Reddel SW, et al. (2010) Patient autoantibodies deplete postsynaptic Muscle Specific Kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J Physiol 588: 3217-3229.
42. Mori S, Yamada S, Kubo S, Chen J, Matsuda S, et al. (2012) Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis. J Neuroimmunol 244: 1-7.
43. Koneczny I, Cossins J, Waters P, Beeson D, Vincent A (2013) MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters. PLOS ONE. 11: e80695.
44. Huijbers MG, Zhang W, Klooster R, Niks EH, Friese MB, et al. (2013) MuSK IgG4 auto-antibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci USA 110: 20783-20788.
45. Westfall TC, Westfall DP (2006) Adrenergic agonists and antagonists. In: Brunton, L. L., Lazo, J. S., Parker, K. L. (eds). Goodman and Gilman's the Pharmacological Basis of Therapeutics McGraw-Hill Inc.
46. Toyka KV, Brachman DB, Pestronk A, Kao I (1975) Myasthenia gravis: passive transfer from man to mouse. Science 190: 397-399.
47. Stacy S, Gelb BE, Koop BA, Windle JJ, Wall KA, et al. (2002) Split tolerance in a novel transgenic model of autoimmune myasthenia gravis. J Immunol 169: 6570-6579. (Pubitemid 36903510)
48. Wood SJ, Slater CR (1997) The contribution of postsynaptic folds to the safety factor for neuromuscular transmission in rat fast- and slow-twitch muscles. J Physiol 500: 165-176. (Pubitemid 27165840)
49. Harris JB, Ribchester RR (1979) The relationship between end-plate size and transmitter release in normal and dystrophic muscles of the mouse. J Physiol 296: 245-265.
50. Plomp JJ, van Kempen GTH, Molenaar PC (1992) Adaptation of quantal content to decreased postsynapitc sensitivity at single endplates in α-bungarotoxin-treated rats. J Physiol 458: 487-499. (Pubitemid 23024605)
51. Cartaud A, Strochlic L, Guerra M, Blanchard B, Lambergeon M, et al. (2004) MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction. J Cell Biol 165: 505-515. (Pubitemid 38679616)
52. Choi KR, Berrera M, Reischl M, Strack S, Albrizio A, et al. (2012) Rapsyn mediates subsynaptic anchoring of PKA type I and stabilisation of acetylcholine receptor in vivo. J Cell Sci 125: 714-723.
53. Roder IV, Choi KR, Reischl M, Petersen Y, Diefenbacher ME, et al. (2010) Myosin Va cooperates with PKA RIα to mediate maintenance of the endplate in vivo. Proc Natl Acad Sci USA 107: 2031-2036.
54. Jha S, Xu K, Maruta T, Oshima M, Mosier DR, et al. (2006) Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK) J Neuroimmunol 175: 107-117. (Pubitemid 43765734)
55. ter Beek PW, Martínez-Martínez P, Losen M, de Baets MH, Wintzen AR, et al. (2009) The effect of plasma from muscle-specific tyrosine kinase myasthenia gravis patients on regenerating endplates. Am J Path 175: 1536-1544.
56. Burke G, Hiscock A, Klein A, Niks EH, Main M, et al. (2013) Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul Disord 23: 170-175.
57. Sartori C, Fang X, McGraw DW, Koch P, Snider ME, et al. (2002) Selected Contribution: Long-term effects of β2-adrenergic receptor stimulation on alveolar fluid clearance in mice. J Appl Physiol 93: 1875-1880. (Pubitemid 36083004)
58. Goldschmidt PL, Frances H, Simon P (1984) Stimulation of beta-adrenergic receptors and spontaneous motor activity in mice. Pharmacol Biochem & Behav 21: 177-180. (Pubitemid 14071915)
59. O'Donnell JM (1993) Differential sensitivity to the effects of albuterol on locomotor activity and operant behavior. Psychopharmacology 113: 243-249.
60. Cairns SP, Dulhunty AF (1993) The effects of β-adrenoceptor activation on contraction in isolated fast- and slow-twitch skeletal muscle fibres of the rat. Br J Pharmacol 110: 1133-1141. (Pubitemid 24005251)
61. Andersson DC, Betzenhauser MJ, Reiken S, Umanskaya A, Shiomi T, et al. (2012) Stress-induced increase in skeletal muscle force requires protein kinase A phosphorylation of the ryanodine receptor. J Physiol 590: 6381-6387.
62. Roatta S, Farina D (2013) Stress-induced increase in muscle force: truth or myth? J Physiol 590: 6381-6387.
63. Koopman R, Gehrig SM, Léger B, Trieu J, Walrand S, et al. (2010) Cellular mechanisms underlying temporal changes in skeletal muscle protein synthesis and breakdown during chronic β-adrenoceptor stimulation in mice. J Physiol 588: 4811-4823.
64. Joassard OR, Durieux AC, Freyssenet DG (2013) β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders. Int J Biochem Cell Biol 45: 2309-2321.